STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors.
Michelle Choe(Baylor College of Medicine), Navin Pinto(Seattle Children's Hospital), Sowmya Pattabhi, Julie R. Park(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Catherine M. Albert(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Wenjun Huang(Lishui Central Hospital), Danielle N. Gamble(Seattle Children's Hospital), Jason Wendler(Pacific Northwest National Laboratory), Prabha Narayanaswamy, Rebecca Gardner(Seattle Children's Hospital), Stephanie Mgebroff(Bloodworks Northwest), Kristy Seidel(Fred Hutch Cancer Center), Mallory Taylor(Center for Cancer and Blood Disorders), Colleen Annesley(Unknown), Christopher Brown, Catherine Lindgren(Unknown), On Ho, Michael C. Jensen(Seattle Children's Hospital)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754